Related Topics:
Fexofenadine
Fexofenadine hydrochloride (brand names include Allegra® and Telfast®) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second-generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first-generation histamine-receptor antagonists.
Common Side Effects
- Nausea
- Vomiting
- Weakness
- Drowsiness, sleepiness
- Depression
Overdose
Reports of
Fexofenadine overdose are infrequent, and because of this, the effects are not well established. No deaths occurred in testing on mice, at 5000mg/kg, which is 110 times the maximum recommended dose for an adult human. Further research shows no deaths in rats at the same concentration, which equates four hundred times the recommended dose in an adult human.
Research on humans ranges from a single 800mg dose, to a twice-daily 690mg dose for a month, with no clinically significant adverse effects, when compared to a placebo.
History
Fexofenadine was developed by
Hoechst Marion Roussel (now part of
Aventis) and approved by the
Food and Drug Administration (FDA) in
1996. Since that time, it has achieved
blockbuster drug status with global sales of $1.87B USD in
2004 (with $1.49B USD coming from the
United States).
References
- Synthesis: J. Org. Chem. 1994, 59, 2620.
- Biological effects: Mol. Pharmacol. 1993, 44, 1240.
External links
Antihistamines | Sanofi-Aventis
Fexofénadine | アレグラ | เฟกโซเฟนาดีน